Based on the Sanofi stock forecast from 0 analysts, the average analyst target price for Sanofi is not available over the next 12 months. Sanofi’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Sanofi is Slightly Bearish, which is based on 3 positive signals and 6 negative signals. At the last closing, Sanofi’s stock price was EUR 89.44. Sanofi’s stock price has changed by +3.66% over the past week, +1.01% over the past month and -13.90% over the last year.
No recent analyst target price found for Sanofi
No recent average analyst rating found for Sanofi
Company Overview Sanofi
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France. Read Less
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides special...Read More
Frequently Asked Questions About Sanofi (SNW:F) Stock
Stock Target Advisor's fundamental analysis for Sanofi's stock is Slightly Bearish.
SNW:F stock's dividend yield is 4.33%.
Our analysis grades SNW:F stock's dividend yield at D+. This means that SNW:F stock's dividend yield is above 67% of the stocks in the Drug Manufacturers - General sector in the F exchange.
Based on this SNW:F may be a average dividend stock for its sector.
Unfortunately we do not have enough data on SNW:F's stock to indicate what its average analyst target is.
SNW:F stock's Price/Earning ratio is 20.12.
Our analysis grades SNW:F stock's Price / Earning ratio at C-. This means that SNW:F stock's Price/Earning ratio is above 30% of the stocks in the Drug Manufacturers - General sector in the F exchange.
Based on this SNW:F may be undervalued for its sector.
The last closing price of SNW:F's stock was EUR 89.44.
The most recent market capitalization for SNW:F is EUR 107.97B.
Unfortunately we do not have enough analyst data on SNW:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Sanofi's stock.
As per our most recent records Sanofi has 86,088 Employees.
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
What not to like
Poor capital utilization
The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.
Poor return on assets
The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
Poor return on equity
The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for SNW:F !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
